In a significant development for the altcoin sector, Canary Capital has announced its decision to file for a staked exchange-traded fund (ETF) centered around Injective Protocol. This strategic move, unveiled on July 17, 2025, aligns with recent guidance from the U.S. Securities and Exchange Commission (SEC), which classifies staking rewards as income.
This regulatory clarity opens the door for asset managers to engage more actively with blockchain-based tokens through delegated staking, a method that allows investors to earn rewards without needing to manage the underlying assets directly. By backing Injective, Canary Capital is not only diversifying its portfolio but also signaling a growing acceptance of decentralized finance (DeFi) solutions within traditional investment frameworks.
The decision to focus on Injective, a platform known for its unique approach to decentralized derivatives trading, reflects a broader trend among institutional investors seeking exposure to innovative blockchain technologies. As the landscape of finance continues to evolve, the integration of staking mechanisms into investment products like ETFs may redefine how investors interact with digital assets.
Canary Capital’s filing is a noteworthy step in the ongoing convergence of traditional finance and cryptocurrency, emphasizing the importance of regulatory guidance in shaping the future of asset management. As the industry watches closely, this development could pave the way for more asset managers to explore similar avenues, further legitimizing the role of cryptocurrencies in mainstream finance.
